PARP1 and prostate carcinoma: The next‐generation PARP inhibitor niraparib is currently undergoing clinical trials, with the Phase III AMPLITUDE study evaluating the efficacy of niraparib in combination with abiraterone acetate and prednisone (AAP) in biomarker‐selected metastatic castration‐sensitive prostate cancer (mCSPC) patients.